Ironwood and Forest to Present 17 Linaclotide-Related Abstracts at Digestive Disease Week® 2012
The oral presentation titled "Efficacy of Linaclotide in Improving
Abdominal Symptoms Rated as Most Severe by Patients with Irritable Bowel
Syndrome with Constipation (IBS-C)" will be presented by
Also being presented are the following poster presentations:
Clinical Posters
-
Mediation Analysis Supports a Direct Effect of Linaclotide on
Relief of Abdominal Pain Independent of Constipation Improvement
(Sa1098), authored by
James E. MacDougall , Ph.D. -
Developing Benchmarks for Clinically Meaningful Change for IBS-C
Symptoms Using Data from Two Phase 3 Trials of Linaclotide
(Sa1094), authored by
Brennan M. Spiegel , M.D. -
The Effect of Co-morbid Psychological Distress on Baseline
Irritable Bowel Syndrome with Constipation Symptoms and Response to
Linaclotide Treatment (Sa1421), authored by
William D. Chey , M.D.
-
Linaclotide Significantly Improved Abdominal Pain Compared with
Placebo in Patients with Irritable Bowel Syndrome Regardless of
Baseline Pain Severity in Two Phase 3 Trials (Mo1856), authored by
Phillip Schoenfeld , M.D. -
Characterization and Association of Abdominal Pain With Anxiety or
Depression in Patients with Irritable Bowel Syndrome with Constipation
(Mo1858), authored by
Eamonn M. Quigley , M.D.
-
Assessing the Percent of Days Linaclotide Improved Abdominal
Symptoms and Stool Frequency in Patients with IBS-C: A Pooled Analysis
of Two Phase 3 Trials (Tu1380), authored by
Satish Rao , M.D. -
Effects of 26 Weeks of Linaclotide Treatment on Adequate Relief and
IBS Severity in Patients with Irritable Bowel Syndrome with
Constipation (Tu1381), authored by
William Chey , M.D. -
Comparison of Responder Rates and Degree of Agreement for
Symptom-Specific and Global-Relief Endpoints in Two Phase 3 Trials of
Linaclotide in IBS-C (Tu1065), authored by
G. Richard Locke , M.D. -
Effects of Linaclotide Treatment on Patient-Reported Ratings of
Change for Symptoms of Irritable Bowel Syndrome with
Constipation: Pooled 12-Week Findings From Two Phase 3 Trials
(Tu1068), authored by
G. Richard Locke , M.D. -
Do Baseline Factors Contribute to Treatment Satisfaction in
Patients with Chronic Constipation Treated With Linaclotide vs Placebo?
(Tu1069), authored by
Phillip S. Schoenfeld , M.D. -
Factors Contributing to Treatment Satisfaction in Patients with
Irritable Bowel Syndrome with Constipation Treated with Linaclotide vs
Placebo (Tu1401), authored by
Anthony Lembo , M.D. -
Effects of Linaclotide on Straining Associated with Bowel Movements
in Patients with Irritable Bowel Syndrome with Constipation (IBS-C): a
Post Hoc Analysis of Pool Data From Two Phase 3 Trials (Tu1423),
authored by
Anthony Lembo , M.D.
Health Economics & Outcomes Research Posters
-
Treatment Patterns and Indicators of Unmet Needs in
Medicaid Patients with Irritable Bowel Syndrome with Constipation and Chronic Constipation (Su1194), authored byRobyn Carson , M.P.H.
-
Impact of Linaclotide Treatment on Work Productivity and Activity
Impairment in Adults with Irritable Bowel Syndrome with
Constipation: Pooled Results from Two Randomized, Double-Blind,
Placebo-Controlled Phase 3 Trials (Tu1402), authored by
Jessica L . Buono, M.P.H.
Preclinical Posters
-
Mechanism of Action for Linaclotide Induced Abdominal Pain Relief (Mo1849),
authored by
Joel Castro -
Cyclic Guanylate Monophosphate (cGMP) Attenuates Responses and
Sensitization of Mouse Colorectal Afferents (Mo1846), authored by
Bin Feng
About Linaclotide
Linaclotide, an investigational drug, is a guanylate cyclase type-C
agonist (GCCA). In preclinical models, linaclotide reduced visceral
hypersensitivity, increased fluid secretion, and accelerated intestinal
transit. The effects on secretion and transit are mediated through
cyclic guanosine monophosphate (cGMP), which is also believed to
modulate the activity of local nerves to reduce pain. Linaclotide is an
orally delivered peptide that acts locally in the gut with no measurable
systemic exposure at therapeutic doses and is intended for once-daily
administration. An issued composition of matter patent for linaclotide
provides protection to 2025 in
About Irritable Bowel Syndrome with Constipation (IBS-C)
IBS-C is a chronic functional gastrointestinal disorder characterized by abdominal pain, abdominal discomfort, and bloating associated with altered bowel habits, and as many as 11 million people in the U.S. suffer from it. IBS-C can have a negative impact on daily living. There are currently few available therapies to treat this disorder.
About Chronic Constipation (CC)
As many as 34 million Americans suffer from symptoms associated with CC and 8.5 million patients have sought treatment. Patients with CC often experience hard and lumpy stools, straining during defecation, a sensation of incomplete evacuation, and fewer than three bowel movements per week, as well as abdominal discomfort and bloating. There is a high rate of dissatisfaction with currently available treatments for CC.
About Digestive Disease Week (DDW)
DDW is the largest international gathering of physicians, researchers
and academics in the fields of gastroenterology, hepatology, endoscopy
and gastrointestinal surgery. Jointly sponsored by the
About
About
Except for the historical information contained herein, this release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements involve a
number of risks and uncertainties, including the potential that the
presentations identified above are not given at all or at the times or
locations specified, in addition to the risk factors listed from time to
time in each of Forest's and Ironwood's Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, and other
Vice
President - Investor Relations
media.relations@frx.com
or
Corporate
Communications
sbrady@ironwoodpharma.com
Source:
News Provided by Acquire Media